Mayne Pharma Group (ASX:MYX) reported Wednesday a fiscal first-half loss of AU$0.323 per diluted share, narrowing from AU$0.878 per diluted share a year earlier.

Revenue for the six months ended Dec. 31, 2024, was AU$213.1 million, up 13% from AU$187.9 million a year earlier.

The company said it expects to grow underlying earnings before interest, taxes, depreciation, and amortization in the second fiscal half via revenue growth and cost leverage.

The firm did not declare a dividend for the reported half-year.